Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration

Hdl Handle:
http://hdl.handle.net/10144/336359
Title:
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration
Authors:
Gabillard, Delphine; Lewden, Charlotte; Ndoye, Ibra; Moh, Raoul; Segeral, Olivier; Tonwe-Gold, Besigin; Etard, Jean-François; Pagnaroat, Men; Fournier-Nicolle, Isabelle; Eholié, Serge; Konate, Issouf; Minga, Albert; Mpoudi-Ngole, Eitel; Koulla-Shiro, Sinata; Zannou, Djimon Marcel; Anglaret, Xavier; Laurent, Christian
Journal:
Journal of Acquired Immune Deficiency Syndromes (1999)
Abstract:
In resource-limited countries, estimating CD4-specific incidence rates of mortality and morbidity among patients receiving antiretroviral therapy (ART) may help assess the effectiveness of care and treatment programmes, identify program weaknesses, and inform decisions.
Publisher:
Lippincott Williams and Wilkins
Issue Date:
15-Apr-2013
URI:
http://hdl.handle.net/10144/336359
DOI:
10.1097/QAI.0b013e3182821821
PubMed ID:
23274931
Language:
en
ISSN:
1944-7884
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorGabillard, Delphineen_GB
dc.contributor.authorLewden, Charlotteen_GB
dc.contributor.authorNdoye, Ibraen_GB
dc.contributor.authorMoh, Raoulen_GB
dc.contributor.authorSegeral, Olivieren_GB
dc.contributor.authorTonwe-Gold, Besiginen_GB
dc.contributor.authorEtard, Jean-Françoisen_GB
dc.contributor.authorPagnaroat, Menen_GB
dc.contributor.authorFournier-Nicolle, Isabelleen_GB
dc.contributor.authorEholié, Sergeen_GB
dc.contributor.authorKonate, Issoufen_GB
dc.contributor.authorMinga, Alberten_GB
dc.contributor.authorMpoudi-Ngole, Eitelen_GB
dc.contributor.authorKoulla-Shiro, Sinataen_GB
dc.contributor.authorZannou, Djimon Marcelen_GB
dc.contributor.authorAnglaret, Xavieren_GB
dc.contributor.authorLaurent, Christianen_GB
dc.date.accessioned2014-11-30T16:11:39Z-
dc.date.available2014-11-30T16:11:39Z-
dc.date.issued2013-04-15-
dc.identifier.citationMortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. 2013, 62 (5):555-61 J. Acquir. Immune Defic. Syndr.en_GB
dc.identifier.issn1944-7884-
dc.identifier.pmid23274931-
dc.identifier.doi10.1097/QAI.0b013e3182821821-
dc.identifier.urihttp://hdl.handle.net/10144/336359-
dc.description.abstractIn resource-limited countries, estimating CD4-specific incidence rates of mortality and morbidity among patients receiving antiretroviral therapy (ART) may help assess the effectiveness of care and treatment programmes, identify program weaknesses, and inform decisions.en_GB
dc.language.isoenen
dc.publisherLippincott Williams and Wilkinsen_GB
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en_GB
dc.subjectHIV/AIDSen_GB
dc.subject.meshAcquired Immunodeficiency Syndromeen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshAfrica South of the Saharaen_GB
dc.subject.meshAnti-HIV Agentsen_GB
dc.subject.meshAsiaen_GB
dc.subject.meshCD4 Lymphocyte Counten_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHIV-1en_GB
dc.subject.meshHumansen_GB
dc.subject.meshIncidenceen_GB
dc.subject.meshLinear Modelsen_GB
dc.subject.meshMaleen_GB
dc.subject.meshYoung Adulten_GB
dc.titleMortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaborationen
dc.identifier.journalJournal of Acquired Immune Deficiency Syndromes (1999)en_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.